ID   TEBP_HUMAN              Reviewed;         160 AA.
AC   Q15185; A8K7D0; B4DHP2; B4DP11; B4DP21; Q8WU70;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JAN-2026, entry version 224.
DE   RecName: Full=Prostaglandin E synthase 3;
DE            EC=5.3.99.3 {ECO:0000269|PubMed:10922363};
DE   AltName: Full=Cytosolic prostaglandin E2 synthase;
DE            Short=cPGES;
DE   AltName: Full=Hsp90 co-chaperone;
DE   AltName: Full=Progesterone receptor complex p23;
DE   AltName: Full=Telomerase-binding protein p23;
GN   Name=PTGES3; Synonyms=P23, TEBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROGESTERONE RECEPTOR-BINDING.
RC   TISSUE=Testis;
RX   PubMed=8114727; DOI=10.1128/mcb.14.3.1956-1963.1994;
RA   Johnson J.L., Beito T.G., Krco C.J., Toft D.O.;
RT   "Characterization of a novel 23-kilodalton protein of unactive progesterone
RT   receptor complexes.";
RL   Mol. Cell. Biol. 14:1956-1963(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4).
RC   TISSUE=Caudate nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 13-65; 72-88 AND 96-122, PHOSPHORYLATION AT SER-113,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [7]
RP   INTERACTION WITH TERT, AND FUNCTION AS A CO-CHAPERONE IN TELOMERASE
RP   HOLOENZYME ASSEMBLY.
RX   PubMed=11274138; DOI=10.1074/jbc.c100055200;
RA   Forsythe H.L., Jarvis J.L., Turner J.W., Elmore L.W., Holt S.E.;
RT   "Stable association of hsp90 and p23, but Not hsp70, with active human
RT   telomerase.";
RL   J. Biol. Chem. 276:15571-15574(2001).
RN   [8]
RP   FUNCTION AS A CHAPERONE.
RX   PubMed=12077419; DOI=10.1126/science.1073051;
RA   Freeman B.C., Yamamoto K.R.;
RT   "Disassembly of transcriptional regulatory complexes by molecular
RT   chaperones.";
RL   Science 296:2232-2235(2002).
RN   [9]
RP   FUNCTION AS A PROSTAGLANDIN SYNTHASE, BIOPHYSICOCHEMICAL PROPERTIES,
RP   CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=10922363; DOI=10.1074/jbc.m003504200;
RA   Tanioka T., Nakatani Y., Semmyo N., Murakami M., Kudo I.;
RT   "Molecular identification of cytosolic prostaglandin E2 synthase that is
RT   functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2
RT   biosynthesis.";
RL   J. Biol. Chem. 275:32775-32782(2000).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; SER-118; SER-148 AND
RP   SER-151, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Pituitary;
RX   PubMed=16807684; DOI=10.1007/s11102-006-8916-x;
RA   Beranova-Giorgianni S., Zhao Y., Desiderio D.M., Giorgianni F.;
RT   "Phosphoproteomic analysis of the human pituitary.";
RL   Pituitary 9:109-120(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate cancer
RT   cells: identification of phosphoproteins in the LNCaP cell line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; SER-148 AND SER-151, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; SER-148 AND SER-151, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-33, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113 AND SER-118, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=22451931; DOI=10.1073/pnas.1200934109;
RA   Boucher D., Blais V., Denault J.B.;
RT   "Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1
RT   proteolysis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:5669-5674(2012).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44; SER-85 AND SER-113, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH EGLN1.
RX   PubMed=24711448; DOI=10.1074/jbc.m113.541227;
RA   Song D., Li L.S., Arsenault P.R., Tan Q., Bigham A.W., Heaton-Johnson K.J.,
RA   Master S.R., Lee F.S.;
RT   "Defective Tibetan PHD2 binding to p23 links high altitude adaption to
RT   altered oxygen sensing.";
RL   J. Biol. Chem. 289:14656-14665(2014).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85; SER-113; SER-148 AND
RP   SER-151, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130 (ISOFORM 4), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [32]
RP   INTERACTION WITH HSP90AA1; FLCN; FNIP1 AND FNIP2.
RX   PubMed=27353360; DOI=10.1038/ncomms12037;
RA   Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D.,
RA   Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W.,
RA   Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W.,
RA   Bratslavsky G., Mollapour M.;
RT   "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance
RT   drug binding.";
RL   Nat. Commun. 7:12037-12037(2016).
RN   [33]
RP   PROTEOLYTIC CLEAVAGE.
RX   PubMed=28863261; DOI=10.1021/acs.biochem.7b00298;
RA   Martini C., Bedard M., Lavigne P., Denault J.B.;
RT   "Characterization of Hsp90 co-chaperone p23 cleavage by caspase-7 uncovers
RT   a peptidase-substrate interaction involving intrinsically disordered
RT   regions.";
RL   Biochemistry 56:5099-5111(2017).
RN   [34]
RP   IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; STIP1; CDC37; PPP5C; TSC1
RP   AND TSC2.
RX   PubMed=29127155; DOI=10.15252/embj.201796700;
RA   Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L.,
RA   Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H.,
RA   Bourboulia D., Bratslavsky G., Wong M., Mollapour M.;
RT   "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding
RT   of kinase and non-kinase clients.";
RL   EMBO J. 36:3650-3665(2017).
RN   [35]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-35 AND LYS-65, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 1-125.
RX   PubMed=10811660; DOI=10.1074/jbc.m003410200;
RA   Weaver A.J., Sullivan W.P., Felts S.J., Owen B.A.L., Toft D.O.;
RT   "Crystal structure and activity of human p23, a heat shock protein 90 co-
RT   chaperone.";
RL   J. Biol. Chem. 275:23045-23052(2000).
CC   -!- FUNCTION: Cytosolic prostaglandin synthase that catalyzes the
CC       oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin
CC       E2 (PGE2) (PubMed:10922363). Molecular chaperone that localizes to
CC       genomic response elements in a hormone-dependent manner and disrupts
CC       receptor-mediated transcriptional activation, by promoting disassembly
CC       of transcriptional regulatory complexes (PubMed:11274138,
CC       PubMed:12077419). Facilitates HIF alpha proteins hydroxylation via
CC       interaction with EGLN1/PHD2, leading to recruit EGLN1/PHD2 to the HSP90
CC       pathway (PubMed:24711448). {ECO:0000269|PubMed:10922363,
CC       ECO:0000269|PubMed:11274138, ECO:0000269|PubMed:12077419,
CC       ECO:0000269|PubMed:24711448}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=prostaglandin H2 = prostaglandin E2; Xref=Rhea:RHEA:12893,
CC         ChEBI:CHEBI:57405, ChEBI:CHEBI:606564; EC=5.3.99.3;
CC         Evidence={ECO:0000269|PubMed:10922363};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=14 uM for PGH2 {ECO:0000269|PubMed:10922363};
CC         Vmax=190 nmol/min/mg enzyme toward PGH2
CC         {ECO:0000269|PubMed:10922363};
CC   -!- PATHWAY: Lipid metabolism; prostaglandin biosynthesis.
CC       {ECO:0000269|PubMed:10922363}.
CC   -!- SUBUNIT: Probably forms a complex composed of chaperones HSP90 and
CC       HSP70, co-chaperones STIP1/HOP, CDC37, PPP5C, PTGES3/p23, TSC1 and
CC       client protein TSC2 (PubMed:29127155). Binds to the progesterone
CC       receptor (PubMed:8114727). Interacts with TERT; the interaction,
CC       together with HSP90AA1, is required for correct assembly and
CC       stabilization of the telomerase holoenzyme complex (PubMed:11274138).
CC       Interacts (via PXLE motif) with EGLN1/PHD2, recruiting EGLN1/PHD2 to
CC       the HSP90 pathway to facilitate HIF alpha proteins hydroxylation
CC       (PubMed:24711448). Interacts with HSP90AA1, FLCN, FNIP1 and FNIP2
CC       (PubMed:27353360). {ECO:0000269|PubMed:11274138,
CC       ECO:0000269|PubMed:24711448, ECO:0000269|PubMed:27353360,
CC       ECO:0000269|PubMed:8114727}.
CC   -!- INTERACTION:
CC       Q15185; Q9UKV8: AGO2; NbExp=3; IntAct=EBI-1049387, EBI-528269;
CC       Q15185; P07900: HSP90AA1; NbExp=9; IntAct=EBI-1049387, EBI-296047;
CC       Q15185; P08238: HSP90AB1; NbExp=7; IntAct=EBI-1049387, EBI-352572;
CC       Q15185; O14654: IRS4; NbExp=2; IntAct=EBI-1049387, EBI-356594;
CC       Q15185; O14802: POLR3A; NbExp=3; IntAct=EBI-1049387, EBI-2515113;
CC       Q15185; Q14190: SIM2; NbExp=2; IntAct=EBI-1049387, EBI-6427100;
CC       Q15185; Q9NRG4: SMYD2; NbExp=3; IntAct=EBI-1049387, EBI-1055671;
CC       Q15185; O94763: URI1; NbExp=3; IntAct=EBI-1049387, EBI-357067;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q3ZBF7}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q15185-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15185-2; Sequence=VSP_055363;
CC       Name=3;
CC         IsoId=Q15185-3; Sequence=VSP_055364;
CC       Name=4;
CC         IsoId=Q15185-4; Sequence=VSP_055365;
CC   -!- DOMAIN: The PXLE motif mediates interaction with EGLN1/PHD2.
CC       {ECO:0000269|PubMed:24711448}.
CC   -!- PTM: Proteolytically cleaved by caspase-7 (CASP7) in response to
CC       apoptosis, leading to its inactivation. {ECO:0000269|PubMed:22451931,
CC       ECO:0000269|PubMed:28863261}.
CC   -!- SIMILARITY: Belongs to the p23/wos2 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L24804; AAA18537.1; -; mRNA.
DR   EMBL; AK291945; BAF84634.1; -; mRNA.
DR   EMBL; AK295208; BAG58204.1; -; mRNA.
DR   EMBL; AK298147; BAG60423.1; -; mRNA.
DR   EMBL; AK298160; BAG60433.1; -; mRNA.
DR   EMBL; AC117378; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471054; EAW96953.1; -; Genomic_DNA.
DR   EMBL; CH471054; EAW96958.1; -; Genomic_DNA.
DR   EMBL; BC003005; AAH03005.1; -; mRNA.
DR   EMBL; BC021167; AAH21167.1; -; mRNA.
DR   CCDS; CCDS31836.1; -. [Q15185-1]
DR   CCDS; CCDS61158.1; -. [Q15185-2]
DR   CCDS; CCDS61159.1; -. [Q15185-3]
DR   CCDS; CCDS61160.1; -. [Q15185-4]
DR   PIR; A56211; A56211.
DR   RefSeq; NP_001269530.1; NM_001282601.2. [Q15185-4]
DR   RefSeq; NP_001269531.1; NM_001282602.2. [Q15185-3]
DR   RefSeq; NP_001269532.1; NM_001282603.2. [Q15185-2]
DR   RefSeq; NP_001269533.1; NM_001282604.1.
DR   RefSeq; NP_001269534.1; NM_001282605.1.
DR   RefSeq; NP_006592.3; NM_006601.6. [Q15185-1]
DR   PDB; 1EJF; X-ray; 2.49 A; A/B=1-125.
DR   PDB; 7KRJ; EM; 2.56 A; C=1-160.
DR   PDB; 7L7I; EM; 3.30 A; E=1-160.
DR   PDB; 7L7J; EM; 3.10 A; C=1-160.
DR   PDBsum; 1EJF; -.
DR   PDBsum; 7KRJ; -.
DR   PDBsum; 7L7I; -.
DR   PDBsum; 7L7J; -.
DR   AlphaFoldDB; Q15185; -.
DR   BMRB; Q15185; -.
DR   EMDB; EMD-23004; -.
DR   EMDB; EMD-23005; -.
DR   EMDB; EMD-23006; -.
DR   EMDB; EMD-23213; -.
DR   EMDB; EMD-23214; -.
DR   SASBDB; Q15185; -.
DR   SMR; Q15185; -.
DR   BioGRID; 115952; 463.
DR   CORUM; Q15185; -.
DR   DIP; DIP-279N; -.
DR   ELM; Q15185; -.
DR   FunCoup; Q15185; 3086.
DR   IntAct; Q15185; 334.
DR   MINT; Q15185; -.
DR   STRING; 9606.ENSP00000482075; -.
DR   ChEMBL; CHEMBL3341580; -.
DR   DrugBank; DB00316; Acetaminophen.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB05036; Grn163l.
DR   SwissLipids; SLP:000000831; -.
DR   GlyGen; Q15185; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q15185; -.
DR   PhosphoSitePlus; Q15185; -.
DR   SwissPalm; Q15185; -.
DR   BioMuta; PTGES3; -.
DR   jPOST; Q15185; -.
DR   MassIVE; Q15185; -.
DR   PaxDb; 9606-ENSP00000482075; -.
DR   PeptideAtlas; Q15185; -.
DR   PRIDE; Q15185; -.
DR   ProteomicsDB; 4234; -.
DR   ProteomicsDB; 4741; -.
DR   ProteomicsDB; 4744; -.
DR   ProteomicsDB; 60486; -. [Q15185-1]
DR   Pumba; Q15185; -.
DR   TopDownProteomics; Q15185-1; -. [Q15185-1]
DR   Antibodypedia; 28360; 761 antibodies from 39 providers.
DR   DNASU; 10728; -.
DR   Ensembl; ENST00000262033.11; ENSP00000262033.6; ENSG00000110958.17. [Q15185-1]
DR   Ensembl; ENST00000414274.7; ENSP00000405299.3; ENSG00000110958.17. [Q15185-3]
DR   Ensembl; ENST00000436399.6; ENSP00000402385.2; ENSG00000110958.17. [Q15185-2]
DR   Ensembl; ENST00000448157.6; ENSP00000414892.2; ENSG00000110958.17. [Q15185-4]
DR   GeneID; 10728; -.
DR   KEGG; hsa:10728; -.
DR   MANE-Select; ENST00000262033.11; ENSP00000262033.6; NM_006601.7; NP_006592.3.
DR   UCSC; uc001slu.6; human. [Q15185-1]
DR   AGR; HGNC:16049; -.
DR   ClinPGx; PA142671118; -.
DR   CTD; 10728; -.
DR   DisGeNET; 10728; -.
DR   GeneCards; PTGES3; -.
DR   HGNC; HGNC:16049; PTGES3.
DR   HPA; ENSG00000110958; Low tissue specificity.
DR   MIM; 607061; gene.
DR   OpenTargets; ENSG00000110958; -.
DR   VEuPathDB; HostDB:ENSG00000110958; -.
DR   eggNOG; KOG3158; Eukaryota.
DR   GeneTree; ENSGT00940000154256; -.
DR   InParanoid; Q15185; -.
DR   OrthoDB; 1564555at2759; -.
DR   PAN-GO; Q15185; 10 GO annotations based on evolutionary models.
DR   PhylomeDB; Q15185; -.
DR   BioCyc; MetaCyc:HS03359-MONOMER; -.
DR   PathwayCommons; Q15185; -.
DR   Reactome; R-HSA-2162123; Synthesis of Prostaglandins (PG) and Thromboxanes (TX).
DR   Reactome; R-HSA-3371497; HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand.
DR   Reactome; R-HSA-3371511; HSF1 activation.
DR   Reactome; R-HSA-3371568; Attenuation phase.
DR   Reactome; R-HSA-8937144; Aryl hydrocarbon receptor signalling.
DR   Reactome; R-HSA-8939211; ESR-mediated signaling.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SABIO-RK; Q15185; -.
DR   SignaLink; Q15185; -.
DR   SIGNOR; Q15185; -.
DR   UniPathway; UPA00662; -.
DR   Agora; ENSG00000110958; -.
DR   BioGRID-ORCS; 10728; 41 hits in 1087 CRISPR screens.
DR   CD-CODE; DEE660B4; Stress granule.
DR   ChiTaRS; PTGES3; human.
DR   EvolutionaryTrace; Q15185; -.
DR   GeneWiki; PTGES3; -.
DR   GenomeRNAi; 10728; -.
DR   Pharos; Q15185; Tbio.
DR   PRO; PR:Q15185; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q15185; protein.
DR   Bgee; ENSG00000110958; Expressed in secondary oocyte and 222 other cell types or tissues.
DR   ExpressionAtlas; Q15185; baseline and differential.
DR   GO; GO:0000781; C:chromosome, telomeric region; IC:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0101031; C:protein folding chaperone complex; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IMP:CAFA.
DR   GO; GO:0005697; C:telomerase holoenzyme complex; IDA:UniProtKB.
DR   GO; GO:0070182; F:DNA polymerase binding; IPI:BHF-UCL.
DR   GO; GO:0051879; F:Hsp90 protein binding; IPI:CAFA.
DR   GO; GO:0050220; F:prostaglandin-E synthase activity; IDA:UniProtKB.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IBA:GO_Central.
DR   GO; GO:0003720; F:telomerase activity; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0051131; P:chaperone-mediated protein complex assembly; IMP:CAFA.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IDA:BHF-UCL.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0046457; P:prostanoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0006457; P:protein folding; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:CAFA.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:1905323; P:telomerase holoenzyme complex assembly; IDA:BHF-UCL.
DR   GO; GO:0000723; P:telomere maintenance; TAS:UniProtKB.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; IDA:BHF-UCL.
DR   CDD; cd00237; p23; 1.
DR   DisProt; DP00358; -.
DR   FunFam; 2.60.40.790:FF:000003; prostaglandin E synthase 3; 1.
DR   Gene3D; 2.60.40.790; -; 1.
DR   InterPro; IPR007052; CS_dom.
DR   InterPro; IPR008978; HSP20-like_chaperone.
DR   InterPro; IPR045250; p23-like.
DR   PANTHER; PTHR22932:SF3; PROSTAGLANDIN E SYNTHASE 3; 1.
DR   PANTHER; PTHR22932; TELOMERASE-BINDING PROTEIN P23 HSP90 CO-CHAPERONE; 1.
DR   Pfam; PF04969; CS; 1.
DR   SUPFAM; SSF49764; HSP20-like chaperones; 1.
DR   PROSITE; PS51203; CS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chaperone; Cytoplasm;
KW   Direct protein sequencing; Fatty acid biosynthesis; Fatty acid metabolism;
KW   Isomerase; Isopeptide bond; Lipid biosynthesis; Lipid metabolism;
KW   Phosphoprotein; Prostaglandin biosynthesis; Prostaglandin metabolism;
KW   Proteomics identification; Reference proteome; Ubl conjugation.
FT   CHAIN           1..160
FT                   /note="Prostaglandin E synthase 3"
FT                   /id="PRO_0000218952"
FT   DOMAIN          1..90
FT                   /note="CS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00547"
FT   REGION          124..160
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           157..160
FT                   /note="PXLE motif"
FT                   /evidence="ECO:0000303|PubMed:24711448"
FT   COMPBIAS        132..153
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            142..143
FT                   /note="Cleavage; by caspase-7"
FT                   /evidence="ECO:0000269|PubMed:28863261"
FT   MOD_RES         33
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         44
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         85
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0Q7"
FT   MOD_RES         113
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|Ref.6, ECO:0007744|PubMed:16807684,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:17487921,
FT                   ECO:0007744|PubMed:18088087, ECO:0007744|PubMed:18318008,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19367720, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         118
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         151
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:24275569"
FT   CROSSLNK        35
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        65
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         63..95
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055363"
FT   VAR_SEQ         96..125
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055364"
FT   VAR_SEQ         126..146
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055365"
FT   STRAND          6..10
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   STRAND          12..19
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   STRAND          24..32
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   STRAND          35..42
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   TURN            43..46
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   STRAND          47..57
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   STRAND          59..68
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   STRAND          73..81
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   STRAND          87..92
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   STRAND          99..101
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   TURN            103..105
FT                   /evidence="ECO:0007829|PDB:1EJF"
FT   HELIX           120..130
FT                   /evidence="ECO:0007829|PDB:7KRJ"
FT   MOD_RES         Q15185-4:130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
SQ   SEQUENCE   160 AA;  18697 MW;  23538BB9D7AFD73F CRC64;
     MQPASAKWYD RRDYVFIEFC VEDSKDVNVN FEKSKLTFSC LGGSDNFKHL NEIDLFHCID
     PNDSKHKRTD RSILCCLRKG ESGQSWPRLT KERAKLNWLS VDFNNWKDWE DDSDEDMSNF
     DRFSEMMNNM GGDEDVDLPE VDGADDDSQD SDDEKMPDLE
//
